Please use this identifier to cite or link to this item: https://cris.library.msu.ac.zw//handle/11408/5653
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSharon R Mutengaen_US
dc.contributor.authorBonolo B Phiniusen_US
dc.contributor.authorMotswedi Andersonen_US
dc.contributor.authorIrene Gobeen_US
dc.contributor.authorMargaret Mokomaneen_US
dc.contributor.authorWonderful T Chogaen_US
dc.contributor.authorGorata Mpebeen_US
dc.contributor.authorMolly Pretorius-Holmeen_US
dc.contributor.authorRosemary Musondaen_US
dc.contributor.authorTendani Gaolatheen_US
dc.contributor.authorMompati Mmalaneen_US
dc.contributor.authorRoger Shapiroen_US
dc.contributor.authorJoseph Makhemaen_US
dc.contributor.authorShahin Lockmanen_US
dc.contributor.authorVlad Novitskyen_US
dc.contributor.authorMax Essexen_US
dc.contributor.authorSikhulile Moyoen_US
dc.contributor.authorSimani Gaseitsiween_US
dc.date.accessioned2023-05-22T07:22:03Z-
dc.date.available2023-05-22T07:22:03Z-
dc.date.issued2023-01-06-
dc.identifier.urihttps://cris.library.msu.ac.zw//handle/11408/5653-
dc.description.abstractBackground,We aimed to determine the prevalence of hepatitis B virus (HBV) infection among people with human immunodeficiency virus (PWH) in rural and periurban communities in Botswana.Methods.PWH from a previous population-based study, the Botswana Prevention Combination Project, which enrolled adults in 30 communities across Botswana (2013–2018), were screened for HBV surface antigen (HBsAg) and HBV core antibody (anti-HBc). HBsAg-positive (HBsAg+) samples were further screened for HBV core immunoglobulin M antibodies (anti-HBc immunoglobulin M [IgM]) and HBV e antigen (HBeAg). We quantified HBV viral load on participants who tested positive (n = 148) and negative for HBsAg (n = 381). Results.Of 3304 participants tested, 271 (8% [95% confidence interval {CI}, 7%–9%]) were HBsAg+ while 1788 (56% [95% CI, 54%–57%]) of 3218 PWH whom we tested had positive anti-HBc. Approximately 88% of HBsAg+ participants were on antiretroviral therapy (ART), 40% and 56% of whom were receiving lamivudine- and tenofovir-containing ART, respectively. Male sex (relative risk ratio [RRR], 1.8 [95% CI, 1.2–2.7]) and the northern geographic region (RRR, 2.5 [95% CI, 1.4–4.7]) were independent predictors of HBV infection (HBsAg+). Of 381 persons with negative HBsAg who were tested for occult HBV, 126 (33% [95% CI, 29%–38%]) had positive HBV DNA. Eleven participants were highly viremic with high HBV viral load while on a lamivudine- or tenofovir-containing regimen. Ten (91%) of these participants also had positive HBeAg serology, while 4 (36%) had positive anti-HBc IgM serology. Conclusions.The prevalence of HBV was high among PWH in Botswana while on ART regimens with activity against HBV.en_US
dc.language.isoenen_US
dc.publisherOxford University Pressen_US
dc.relation.ispartofOpen Forum Infectious Diseasesen_US
dc.subjectAfrica,en_US
dc.subjectBotswanaen_US
dc.subjecthepatitis B virusen_US
dc.subjecthuman immunodeficiency virusen_US
dc.subjectoccult HBVen_US
dc.titleHigh Prevalence of Hepatitis B Virus Infection Among People With HIV in Rural and Periurban Communities in Botswanaen_US
dc.typeresearch articleen_US
dc.identifier.doihttps://doi.org/10.1093/ofid/ofac707-
dc.contributor.affiliationDepartment of Applied Biological Sciences and Biotechnology, Faculty of Science and Technology, Midlands State University, Gweru, Zimbabwe.en_US
dc.contributor.affiliationBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana. School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana.en_US
dc.contributor.affiliationBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana. School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana.en_US
dc.contributor.affiliationSchool of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana.en_US
dc.contributor.affiliationSchool of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana.en_US
dc.contributor.affiliationBotswana Harvard AIDS Institute Partnership, Gaborone, Botswanaen_US
dc.contributor.affiliationBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.Department of Biological Sciences, Faculty of Sciences, University of Botswana, Gaborone, Botswana.en_US
dc.contributor.affiliationDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.en_US
dc.contributor.affiliationBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana. Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.en_US
dc.contributor.affiliationBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.en_US
dc.contributor.affiliationBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.en_US
dc.contributor.affiliationBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana. Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.en_US
dc.contributor.affiliationBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana. Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.en_US
dc.contributor.affiliationBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.en_US
dc.contributor.affiliationDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.en_US
dc.contributor.affiliationDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.en_US
dc.contributor.affiliationDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.en_US
dc.contributor.affiliationBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.en_US
dc.relation.issn2328-8957en_US
dc.description.volume10en_US
dc.description.issue1en_US
dc.description.startpage1en_US
dc.description.endpage15en_US
item.openairetyperesearch article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextWith Fulltext-
item.cerifentitytypePublications-
item.grantfulltextopen-
item.languageiso639-1en-
Appears in Collections:Research Papers
Show simple item record

Page view(s)

86
checked on Nov 22, 2024

Download(s)

14
checked on Nov 22, 2024

Google ScholarTM

Check

Altmetric


Items in MSUIR are protected by copyright, with all rights reserved, unless otherwise indicated.